Navigation Links
BioElectronics Corporation's New Commercial Airing Nationally Advertising Initiative Will Reach 15,000,000 Homes Nationwide
Date:4/9/2008

FREDERICK, Md., April 9, 2008 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL), announced today that the company will start airing a new commercial for its ActiPatch (TM) technology on Bloomberg Television, April 14, 2008. The company has initiated an advertising contract that calls for the informational commercial to run for the next two weeks, and will reach millions of viewers daily. CEO Andrew Whelan comments, "This is a new initiative for BioElectronics Corporation and we are excited that this commercial will inform consumers, physicians, and distributors about our ActiPatch(TM) products. This national advertisement should help us reach a new level in both product and brand awareness."

The new bio-electronic super-bandage has produced significant rapid healing results in trials and has already received regulatory clearance by the FDA for the treatment of edema following blepharoplasty.

"ActiPatch (TM)" is very thin, easily applied and comfortable to wear on an injured area. The patch effectively minimizes pain and swelling. Physicians are so impressed with the power of the patch that they are providing it to their patients for uses beyond plastic surgery recovery. Trials are ongoing in multiple areas.

The new ActiPatch(TM) retail product line targets five common conditions that affect hundreds of millions of people throughout the world: 1) Back pain, 2) Foot and ankle pain, including ankle sprains and plantar fasciitis, 3) Knee pain, 4) Arm and wrist pain, including carpal tunnel and tennis elbow. BioElectronics has planned an aggressive retail introduction of these products for locations outside of the United States where regulatory clearance has been received. Distribution is expected in Canada, Italy, Netherlands, Australia, Mexico, United Kingdom, the Middle East, and other countries over the next few months.

About BioElectronics

BioElectronics Corporation is the maker of the ActiPatch(TM). ActiPatch(TM) is a drug free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch(TM) delivery system, using patented technology, provides a cost-effective patient friendly method to reduce soft tissue pain and swelling.

For more information visit: http://www.bioelectronicscorp.com

Safe Harbor Statement

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies In light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the company has no control.


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. BioElectronics Corporation Receives 2007 Economic Development Innovator of the Year Award
2. BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales
3. BioElectronics Corporation (BIEL) SqueezeTrigger Price is $0.11
4. Nationally Recognized Corporations and Retailers Rally Behind breastcancer.org
5. BDSI secures US commercial partnership for BEMA Fentanyl with Meda AB
6. WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana
7. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
8. OmniGuide Begins European Commercialization
9. Creating Effective Cross-Functional Teams for Pharmaceutical Commercialization Success
10. Commercial Insurers Reimbursement Rate to New Yorks Community Health Centers Jeopardizes Care
11. Anesiva to Unveil Zingo(TM) Commercialization Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
Breaking Medicine Technology: